We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
251
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$309K 0.01%
103
-137
-57% -$4.26K
GNMX
252
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
$297K 0.01%
+533
New +$3.04K
ANTH
253
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$297K 0.01%
11,775
-725
-6% -$18.3K
DRNA
254
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$294K 0.01%
+50,000
New +$175K
QRHC icon
255
Quest Resource Holding
QRHC
$27.6M
$281K 0.01%
138,980
-25,484
-15% -$59.7K
SGYPW
256
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$268K 0.01%
+348,743
New +$210K
QNRX
257
Quoin Pharmaceuticals
QNRX
$8.59M
$264K 0.01%
+1
New +$494K
OCUL icon
258
Ocular Therapeutix
OCUL
$1.83B
$262K 0.01%
+38,100
New +$232K
RNVAZ
259
DELISTED
Rennova Health, Inc. Warrant
RNVAZ
$258K 0.01%
+3,682,014
New +$313K
CSCI
260
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$254K 0.01%
+7
New +$2.45K
DRRX
261
CALL
DELISTED
DURECT Corp
DRRX
$245K 0.01%
176
+99
+129% +$1.63K
STML
262
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$240K 0.01%
+222
New +$1.8K
FLXN
263
DELISTED
Flexion Therapeutics, Inc.
FLXN
$238K 0.01%
12,176
-88,624
-88% -$1.5M
SLNO
264
DELISTED
Soleno Therapeutics
SLNO
$236K 0.01%
3,276
-3,407
-51% -$258K
TXMD icon
265
TherapeuticsMD
TXMD
$23.8M
$232K 0.01%
+681
New +$249K
CSCI
266
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$230K 0.01%
670
-1,988
-75% -$697K
ITCI
267
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$226K 0.01%
14,800
-57,143
-79% -$2.31M
ITCI
268
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$226K 0.01%
148
-1,319
-90% -$53.3K
VYNT
269
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$191K 0.01%
727
-604
-45% -$185K
ATHX
270
DELISTED
Athersys, Inc. Common Stock
ATHX
$190K 0.01%
3,566
-104
-3% -$5.38K
CLRBW
271
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$188K 0.01%
228,788
-1,225
-0.5% -$392
NVAX icon
272
PUT
Novavax
NVAX
$1.21B
$176K 0.01%
42
-480
-92% -$62K
SRNE
273
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$162K 0.01%
20,986
-232,819
-92% -$1.57M
NTRA icon
274
CALL
Natera
NTRA
$36.4B
$161K 0.01%
145
+1
+0.7% +$11
SGMO
275
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$152K 0.01%
+32,804
New +$167K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.